Date: 2016-01-06
Type of information: Nomination
Compound:
Company: Spark Therapeutics (USA - PA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 6, 2016, Spark Therapeutics announced that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies, has been named to the company’s Board of Directors. Ms. Zoth has served in senior financial roles in a variety of commercial-stage companies over a 30-year career, including serving as Chief Financial Officer for MedImmune before its acquisition by AstraZeneca in 2007, and leadership experience at PSINet, Sodexho, Marriott International and PepsiCo, Inc. She began her career as an auditor with Ernst & Young. She has served as a member of multiple public and private company boards over the past decade in the biopharmaceutical industry.
Financial terms:
Latest news:
